George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
From what we're being told CimetrA is effective and more affordable and it can be administered at home rather than hospitals. Covid is going nowhere in a hurry and sure there will be plenty of demand. CimetrA is 1/7 of the price of antiviral drugs. We just need USA to say its a success and could lead to universal use. Not forgetting this is only one of MGCs treatments. Fingers crossed more good news on its way.
Risingtothestars, all sounds good and how proven is it? We know mercks is 50%. Whats MGC's? Mercks goes into phase 3, and gets 1.2bill dollars after approval, MGC is already in phase 3, near completion and it gets..... zero. Hmmm . Not saying it wont be a success, just saying they will get left overs. Others are now coming to market.... mgc need to prove how good "good" is to wet the appetite of those with the purse strings. New flow is sketchy at best, often fluffed up and yet to get explanation for their partners delay in their own deal? Great transparent coms. Even the dates on their FDA application dont match with their RNS claims, and as for Robbie coming over all Elon musk on twitter was.... pathetic. Sigh. Still hold for gold, but holding for the wonder treatment? Looks like.we will be taking Mercks before winter.
He says several not seven...that's what confused me
Important to keep up to speed with the news flow
Fill your boots
If you have been keeping track of MGC Pharma’s announcements across the late summer, you may have seen a series of updates relating to CimetrA™, specifically our Supply & Distribution agreement with partner AMC Holdings and their subsequent initial product order of $3 million in the relationship’s first year. This partnership has opened the door for us to enter the world’s largest healthcare market, the United States, as well as build a platform to present CimetrA™ as a viable treatment for Covid-19.
Since that announcement in September, we’ve gone from strength to strength, fast-tracking sales of CimetrA™ and working with the likes of the University of South Florida in Tampa and the Holy Cross Hospital in Fort Lauderdale, to help push our approval process in the States, and major Indian distributor, Medipharm, on Emergency Approval in India. We also have approvals with several countries across Eastern Europe on the horizon. All of these efforts are extensive and laborious regulatory processes that we are putting many resources towards, for a few reasons: a) the more approvals the better, and b) we believe in this product and its potential to be a game-changer for dealing with COVID-19 positive patients.
For more specific information about CimetrA™ and the way it works, please review the below presentation which summarizes things very nicely, but I’ll provide an even higher level review with a comparison point you may find interesting.
Last week, a big fuss was made about Merck applying for Emergency Authorization for their, Molnupiravir, an antiviral that has shown efficacy in “reducing the risk of sick people finding themselves hospitalized”. The rate of efficacy for this claim was approximately 50%. The price of this product is targeted at 700 dollars. In our clinical trials, CimetrA™ has been proven to halt the progress of the Cytokine Storm, the chief cause of death in COVID-19. The price of CimetrA™, or to be specific, the price that we recommend it be sold to consumers, is below 100 dollars. Additionally, CimetrA™ can be used at home by the patient and has no side effects.
In summary, MGC has a more affordable and effective product, which is safe to use and easier to dispense (a very important statistic as well), to combat COVID-19 infections, available on the market. We have come by our data and our formulation in a manner that is consistent with every product to come out of big pharma in the past thirty years – quantified, tested, verified, double-checked and then brought to market.
Again, this is with no disrespect to Merck and their accomplishments; rather it is a testament to the really great work the MGC team have put in during recent months to make CimetrA™ viable as a COVID-19 treatment a near-reality.
What does the supply of CimetrA™ mean to both patients and healthcare providers within our global markets?
Firstly, for patients, it provides a whole new treatment potential to fight COVID-19. Dosage will
Read Ruby's tweet on 15th October https://twitter.com/MGC_Pharma/status/1450087267222048771?t=d878h3VSzkKpTzUVnnw8lQ&s=19
How did you get to 7 Eastern European countries?
I have the patience, just venting.
7 Eastern European countries in the pipeline and India within touching distance. BIG CONTRACTS coming which in my mind only means potential for big increases in the SP!! For those people not interested, just move on and find another company
At last someone who realises the magnitude of what we may have here GLA
I don't suppose a $24m minimum contract with the USA is a revenue maker, with potential for more. Deals are coming if only people had some patience
He's busy comparing his untrialled revenueless product to one that has just secured big deals.
We could do with some decent news here, no good Roby making claims like MXC is in the same league as Pfizer and not backing it up with some stonking updates.
Price goes up
Coincidence...